You are here: Home: Meet The Professors Vol. 1 2003: Case 5: Select publications

 

Select publications: Capecitabine in metastatic breast cancer

Capecitabine/bevacizumab compared to capecitabine alone in pretreated metastatic breast cancer: Results of a Phase III study. Clin Breast Cancer 2003;3(6):375-7.

Ahn Sr J et al. Phase II study of a combination chemotherapy of capecitabine and vinorelbine in metastatic breast cancer with previous exposure to anthracycline and taxane: Preliminary results. Proc ASCO 2002: Abstract 2030.

Andres R et al. Capecitabine plus gemcitabine is an active combination for patients with metastatic breast cancer refractory to anthracyclines and taxanes. Proc ASCO 2003;Abstract 356.

Bauer-Kosinska B et al. Capecitabine monotherapy in the treatment of patients with chemotherapy pre-treated metastatic breast cancer. Proc ASCO 2003;Abstract 320.

Biganzoli L et al. Moving forward with capecitabine: A glimpse of the future. Oncologist 2002;7(Suppl 6):29-35. Abstract.

Blum J. The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer. Oncologist 2001;6(1):56-64. Abstract.

Chan S et al. A phase II study on an all-oral regimen of capecitabine (XelodaTM) (X), idarubicin (I) and cyclophosphamide (C) (XIC) for metastatic breast cancer — Safety, efficacy and quality of life. Proc ASCO 2002: Abstract 2023.

Crown J. Nonanthracycline containing docetaxel-based combinations in metastatic breast cancer. Oncologist 2001;6(Suppl 3):17-21. Abstract.

Fumoleau P et al. Capecitabine (Xeloda) in patients with advanced breast cancer (ABC), previously treated with anthracyclines and taxanes: Results of a large phase II study. Proc ASCO 2002: Abstract 247.

Ghosn M et al. Vinorelbine (Navelbine) IV and capecitabine (VINOCAP) as front line chemotherapy in metastatic breast cancer (MBC). Proc ASCO 2002: Abstract 1978.

Gligorov J et al. Capecitabine and oral vinorelbine in metastatic breast cancer: Preliminary experience. Proc ASCO 2003;Abstract 351.

Kaklamani VG, Gradishar WJ. Role of capecitabine (Xeloda) in breast cancer. Expert Rev Anticancer Ther 2003;3(2):137-44. Abstract.

Lago S et al. Quality of life (QoL) in metastatic breast cancer (MBC) patients taking capecitabine. Proc ASCO 2003;Abstract 2994.

Leonard RC et al. Capecitabine named-patient programme for patients with advanced breast cancer. The UK experience. Eur J Cancer 2002;38(15):2020-4. Abstract.

Maher JF, Villalona-Calero MA. Taxanes and capecitabine in combination: Rationale and clinical results. Clin Breast Cancer 2002;2(4):287-93. Abstract.

Miles D et al. Combination versus sequential single-agent therapy in metastatic breast cancer. Oncologist 2002;7(Suppl 6):13-9. Abstract.

O'Shaughnessy J. Capecitabine and docetaxel in advanced breast cancer: Analyses of a phase III comparative trial. Oncology (Huntingt) 2002;16(10 Suppl 12):17-22. Abstract.

O'Shaughnessy J. Clinical experience of capecitabine in metastatic breast cancer. Eur J Cancer 2002;38(Suppl 2):10-4. Abstract.

O'Shaughnessy JA et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001;12(9):1247-54. Abstract.

O'Shaughnessy J et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002;20(12):2812-23. Abstract.

O'Shaughnessy J et al. Treatment for anthracycline-pretreated metastatic breast cancer. Oncologist 2002;7(Suppl 6):4-12. Abstract.

Procopio G et al. A Phase II study of capecitabine in elderly patients with advanced breast cancer. Proc ASCO 2001:Abstract 3134.

Procopio G et al. Safety and activity of capecitabine in elderly patients (pts) with advanced breast cancer (ABC). Proc ASCO 2003;Abstract 3050.

Scarfe AG et al. Interim results of a phase II study of weekly docetaxel (Taxotere®) combined with intermittent capecitabine (Xeloda®) for patients with anthracycline pretreated metastatic breast cancer. Proc ASCO 2002:Abstract 1984.

Seidman AD. Monotherapy options in the management of metastatic breast cancer. Semin Oncol 2003 Apr;30(2 Suppl 3):6-10. Abstract.

Seidman AD et al. Single-agent capecitabine: A reference treatment for taxane-pretreated metastatic breast cancer? Oncologist 2002;7(Suppl 6):20-8. Abstract.

Semiglazov TY et al. Oral capecitabine (Xeloda) in the treatment of anthracycline-refractory, anthracycline and docetaxel-refractory metastatic breast cancer (MBC). Proc ASCO 2002: Abstract 2061.

Soto C et al. Capecitabine (X) plus docetaxel (T) vs capecitabine plus paclitaxel (P) vs sequential capecitabine then taxane in anthracycline pretreated patients (pts) with metastatic breast cancer: Early results. Proc ASCO 2003;Abstract 28.

Talbot DC et al. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002;86(9):1367-72. Abstract.

Venturini M et al. Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma. Cancer 2003;97(5):1174-80. Abstract.

Wagstaff AJ et al. Capecitabine: A review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer. Drugs 2003;63(2):217-36. Abstract.

Wilke H. Future treatment options with capecitabine in solid tumours. Eur J Cancer 2002;38 (Suppl 2):21-5. Abstract.

 

Table of Contents Top of Page 

 

Home · Search

 
CME Information
Faculty
Editor's Note
 
CASE 1: Disease recurrence and brachial plexopathy during the third trimester of pregnancy
- Select publications
 
CASE 2: Unresectable local recurrence in the pectoralis major after breast-conserving
surgery
- Select publications
 
CASE 3: Pulmonary metastases and mild shortness of breath
- Select publications
 
CASE 4: HER2-positive metastases to the lung and residual local breast cancer after lumpectomy
- Select publications
 
CASE 5: Liver metastases and mild hepatic encephalopathy
- Select publications
 
CASE 6: Ascites and pleural effusion ten years after primary breast cancer
- Select publications
Home · Contact us
Terms of use and general disclaimer